Evidence map›Paper›PMID 35064450›Full record

ArticleJournal of neuro-oncology2022

Quality of life following concurrent temozolomide-based chemoradiation therapy or observation in low-grade glioma.

Deborah Y Park, Martin C Tom, Wei Wei, Surabhi Tewari, Manmeet S Ahluwalia, Jennifer S Yu, Samuel T Chao, John H Suh, David Peereboom, Glen H J Stevens and 10 more

Abstract read
PubMed Publisher
In one paragraph

Article in Journal of neuro-oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
0.6field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it, 5 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors at 5 institutions in 1 country.

Deborah Y ParkCleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland Clinic, Cleveland, OH, USA.ORCID http://orcid.org/0000-0003-3282-3557
Martin C TomDepartment of Radiation Oncology, Miami Cancer Institute, Baptist Health South Florida, Miami, FL, USA.
Wei WeiDepartment of Quantitative Health Sciences, Lerner Research Institute, Cleveland Clinic, 9500 Euclid Avenue / CA-60, Cleveland, OH, 44195, USA.
Surabhi TewariCleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland Clinic, Cleveland, OH, USA.
Manmeet S AhluwaliaDepartment of Radiation Oncology, Miami Cancer Institute, Baptist Health South Florida, Miami, FL, USA.
Jennifer S YuCleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland Clinic, Cleveland, OH, USA.
Samuel T ChaoCleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland Clinic, Cleveland, OH, USA.
John H SuhCleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland Clinic, Cleveland, OH, USA.
David PeereboomCleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland Clinic, Cleveland, OH, USA.
Glen H J StevensCleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland Clinic, Cleveland, OH, USA.
Gene H BarnettCleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland Clinic, Cleveland, OH, USA.
Lilyana AngelovCleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland Clinic, Cleveland, OH, USA.
Alireza M MohammadiCleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland Clinic, Cleveland, OH, USA.
Thomas HoganDepartment of Neuropsychology, Cleveland Clinic, Cleveland, OH, USA.
Courtney KisselDepartment of Neuropsychology, Cleveland Clinic, Cleveland, OH, USA.
Brittany LapinDepartment of Quantitative Health Sciences, Lerner Research Institute, Cleveland Clinic, 9500 Euclid Avenue / CA-60, Cleveland, OH, 44195, USA.
Isabel SchuermeyerDepartment of Psychiatry, Louis Stokes Cleveland VA Medical Center, Cleveland, OH, USA.
Michael W ParsonsNeuro-Oncology Center and Department of Psychiatry, Massachusetts General Hospital, Boston, MA, USA.
Richard NaugleCleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland Clinic, Cleveland, OH, USA.
Erin S MurphyCleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland Clinic, Cleveland, OH, USA. murphye3@ccf.org.
Cleveland Clinic · USCleveland Clinic Lerner College of Medicine · USBaptist Hospital of Miami · USLouis Stokes Cleveland VA Medical Center · USMassachusetts General Hospital · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeLow-grade glioma (LGG) exhibits longer median survival than high-grade brain tumors, and thus impact of our therapies on patient quality of life remains a crucial consideration. This study evaluated the effects of concurrent temozolomide-based chemoradiation (RT + TMZ) or observation on quality of life (QOL) in patients with low-grade glioma.

methodsWe completed a retrospective cross-sectional study of adults with LGG who underwent surgery with known molecular classification from 1980 to 2018. Postoperatively, patients were either observed or received adjuvant concurrent temozolomide-based chemoradiation. EQ-5D and PHQ-9 depression screen were completed before outpatient visits every 2-3 months. Baseline score was defined as ± 30 days within initial operation.

resultsOf the 63 patients (mean age 44 ± 17 years, 51% female) with baseline EQ-5D or PHQ-9 depression screen data and at least one follow-up measure, 30 (48%) were observed and 33 (52%) received RT + TMZ. No significant decline was seen in EQ-5D or PHQ-9 scores at 3, 6, 9, 12, and 24 months compared to baseline scores for all patients. At each time point, there was no significant difference between those who were observed or received adjuvant therapy. The linear mixed model estimating PHQ-9 value or EQ-5D index demonstrated that there was no significant difference in PHQ-9 or EQ-5D index between treatment groups (p = 0.42 and p = 0.54, respectively) or time points (p = 0.24 and p = 0.99, respectively).

conclusionOur study found no significant decline in patient QOL or depression scores as assessed by patient- reported outcome measures for patients with low-grade glioma up to 2 years following surgery. We found no difference between RT + TMZ compared to observation during this time frame. Additional follow-up can help identify the longer-term impact of treatment strategy on patient experience.

Indexed as

Brain NeoplasmsChemoradiotherapyGliomaQuality of LifeTemozolomideWatchful WaitingAdultCross-Sectional StudiesFemaleHumansMaleMiddle AgedNeoplasm GradingRetrospective StudiesTreatment OutcomeTemozolomideChemoradiationEQ-5DLow grade gliomaPHQ-9Quality of lifeTemozolomide

Identifiers

PMID35064450
OpenAlexW4206942583

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.